QNZ (EVP4593)
目录号:S4902 Purity: 99.92%
QNZ (EVP4593)有效抑制NF-κB激活和TNF-α产生,在Jurkat T细胞中IC50分别为11 nM和7 nM。
CAS: 545380-34-5
客户使用Selleck的QNZ (EVP4593)发表文献143篇
- Cancer Cell, 2022 S1535-6108(22)00312-9
- Cell, 2020 182(3):685-712.e19
- Immunity, 2018 49(6):1049-1061
- Bioact Mater, 2024 36:238-255
- Nat Commun, 2024 15(1):1835
- Cell Rep Med, 2024 5(2):101420
- Redox Biol, 2024 69:103031
- J Immunother Cancer, 2024 12(12)e009627
- J Adv Res, 2024 S2090-1232(24)00499-5
- iScience, 2024 27(2):108857
- Front Pharmacol, 2024 15:1420602
- Cancers (Basel), 2024 16(20)3491
- J Inflamm Res, 2024 17:10183-10197
- Adv Sci (Weinh), 2023 10(15):e2300116
- Acta Pharm Sin B, 2023 13(8):3352-3364
- Cell Death Differ, 2023 10.1038/s41418-023-01141-0
- Cancer Lett, 2023 10.1016/j.canlet.2023.216427
- Cell Death Dis, 2023 14(9):627
- Cell Mol Biol Lett, 2023 28(1):62
- Biomedicine & Pharmacotherapy, 2023 114638
- Biomed Pharmacother, 2023 162:114638
- Cell Death Discov, 2023 9(1):456
- Cells, 2023 12(11)1461
- Cells, 2023 12(12)1624
- Front Pharmacol, 2023 10.3389/fphar.2023.1159075
- Int J Mol Sci, 2023 24(9)7707
- Front Cell Dev Biol, 2023 11:1062229
- Thorac Cancer, 2023 14(19):1843-1856
- Iran J Biotechnol, 2023 21(1):e3117
- The University of Auckland, 2023
- MicroPubl Biol, 2023 2023:
- Nat Commun, 2022 13(1):6226
- Cell Death Differ, 2022 10.1038/s41418-022-00940-1
- J Neuroinflammation, 2022 19(1):205
- Cell Death Dis, 2022 13(5):495
- Cell Death Dis, 2022 13(4):420
- Int J Biol Macromol, 2022 208:890-900
- Biomed Pharmacother, 2022 145:112437
- Front Immunol, 2022 13:966514
- Cell Death Discov, 2022 8(1):113
- iScience, 2022 25(10):105182
- Mol Ther Oncolytics, 2022 24:873-886
- Int J Mol Sci, 2022 23(22)13673
- Int J Mol Sci, 2022 23(5)2409
- Int J Mol Sci, 2022 23(6)3280
- Int Immunopharmacol, 2022 102:108380
- Oncotarget, 2022 13:944-959
- Cytokine, 2022 155:155898
- BMC Cancer, 2022 22(1):457
- Nat Commun, 2021 12(1):2788
- J Clin Invest, 2021 142677
- Hepatology, 2021 74(4):1971-1993
- Leukemia, 2021 10.1038/s41375-021-01487-9
- Cell Rep, 2021 34(7):108744
- J Transl Med, 2021 19(1):163
- Front Immunol, 2021 12:753412
- J Infect Dis, 2021 jiab272
- Cells, 2021 10(10)2688
- Sci Rep, 2021 11(1):24014
- Sci Rep, 2021 11(1):2974
- Mol Cell Endocrinol, 2021 535:111390
- Breast Cancer, 2021 10.1007/s12282-021-01224-1
- Biomed Res Int, 2021 2021:8844119
- Fitoterapia, 2021 156:105071
- Cell Regen, 2021 10(1):9
- Cell Death Differ, 2020 10.1038/s41418-020-00656-0
- Gut Microbes, 2020 12(1):1-20
- J Exp Clin Cancer Res, 2020 39(1):170
- Cancer Sci, 2020
- Front Pharmacol, 2020 11:598939
- Int J Mol Sci, 2020 16;21(10):E3527
- Virol Sin, 2020 10.1007/s12250-020-00320-4
- Aging (Albany NY), 2020 12(24):26029-26046
- J Biol Chem, 2020 10.1074/jbc.RA119.010734
- Environ Toxicol, 2020 10.1002/tox.22942
- J Immunol, 2020 205(5):1306-1317
- J Immunol, 2020 20 pii: ji1901089
- Oncol Rep, 2020 43(5):1558-1568
- Onco Targets Ther, 2020 13:8989-9003
- Int J Biochem Cell Biol, 2020 118:105644
- Exp Cell Res, 2020 388(2):111818
- Eur Rev Med Pharmacol Sci, 2020 24(9):4642-4651
- Kaohsiung J Med Sci, 2020 10.1002
- Neural Plast, 2020 2020:8872296
- Korean Circ J, 2020 50(5):443-457
- Anticancer Res, 2020 40(12):6723-6732
- Mol Biomed, 2020 1(1):12
- Sci Transl Med, 2019 9(415)
- Nat Commun, 2019 10(1):3708
- J Exp Clin Cancer Res, 2019 17;38(1):167
- Cancer Res, 2019 79(9):2415-2425
- J Immunother Cancer, 2019
- Cell Death Dis, 2019 10(11):863
- Oncogene, 2019 38(49):7433-7446
- Biomed Pharmacother, 2019 116:109032
- Oxid Med Cell Longev, 2019 2019:2853534
- J Cell Mol Med, 2019 23(7):4666-4678
- Biochim Biophys Acta Mol Cell Res, 2019 1866(10):1533-1543
- Am J Physiol Lung Cell Mol Physiol, 2019 316(3):L487-L497
- FASEB J, 2019 33(11):11776-11790
- Carcinogenesis, 2019 10.1093/carcin/bgy157
- Sci Rep, 2019 9(1):8401
- Molecules, 2019 24(18)
- BMC Cancer, 2019 19(1):1192
- Biochem Biophys Res Commun, 2019 509(1):16-23
- Am J Transl Res, 2019 11(8):5114-5121
- Cell Death Dis, 2018 9(6):587
- Oncogene, 2018
- Cell Mol Life Sci, 2018 75(14):2643-2661
- Oncogene, 2018 10.1038/s41388-018-0479-6
- Antiviral Res, 2018 153:39-48
- Oncoimmunology, 2018 7(7):e1442167
- PLoS Pathog, 2018 14(9):e1007109
- PLoS Pathog, 2018 14(8):e1007223
- Biochem Pharmacol, 2018 156:120-134
- Int J Mol Med, 2018 42(2):2972
- Front Oncol, 2018 8:632
- Exp Cell Res, 2018 10.1016/j.yexcr.2018.10.006
- Mol Med Rep, 2018 17(4):5970-5975
- Biochem Biophys Res Commun, 2018 504(4):797-804
- Anticancer Res, 2018 38(4):2161-2167
- Anticancer Res, 2018 38(9):5201-5210
- Nat Commun, 2017 8:14091
- Genes Dev, 2017 31(20):2099-2112
- Osteoarthritis Cartilage, 2017 25(11):1890-1899
- Am J Physiol Cell Physiol, 2017 313(6):C612-C620
- Oncotarget, 2017 8(54):92841-92854
- Int J Oncol, 2017 50(2):555-566
- Sci Rep, 2017 7(1):13846
- Cell Physiol Biochem, 2017 41(1):91-100
- PLoS One, 2017 12(11):e0188317
- World J Urol, 2017 35(8):1213-1221
- Leukemia, 2016 30(1):86-93
- Nephrol Dial Transplant, 2016 pii: gfw058
- Oncotarget, 2016 7(31-:50161-50179
- Am J Physiol Renal Physiol, 2016 310(11):F1284-94
- PLoS One, 2016 11(7):e0159089
- Cereb Cortex, 2016 10.1093/cercor/bhw169
- Biomed Res Int, 2016 2016:3296437
- J Asthma, 2016 53(10):989-98
- Nat Commun, 2015 6:7956
- Diabetes, 2015 64(12):4061-74
- Toxicol Appl Pharmacol, 2015 289(2):133-41
化学信息&溶解度
分子量 | 356.42 |
分子式 | C22H20N4O |
CAS号 | 545380-34-5 |
Smiles | C1=CC=C(C=C1)OC2=CC=C(C=C2)CCNC3=NC=NC4=C3C=C(C=C4)N |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 71 mg/mL ( 199.2 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 71 mg/mL ( 199.2 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:3.55mg/ml
(9.96mM)
操作示例:以 1 mL 工作液为例,取50μL71mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
|
0.5% hydroxyethyl cellulose
浓度:10mg/ml
(28.06mM)
操作示例:以1 mL工作液为例,取10 mg此产品,加入到1ml的0.5% hydroxyethyl cellulose澄清溶液,混合均匀使其成为均匀悬浊液。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。